The DOI matches its Crossref record.
Signal Transduction Pathway Targets for Anticancer Drug Discovery
Abstract
There are currently over 80 agents officially approved for the treatment of cancer world-wide. However, the most common epithelial cancers, which cause greater than 75percenr of cancer deaths, remain incurable. Most drugs have been developed empirically by testing large numbers of chemicals on rapidly growing transplantable rodent tumors, and more recently, human tumor xenografts. This approach has identified prodeminantly DNA-active drugs that are considerably toxic and have limited efficacy. Novel molecular targets, which are selective for neoplastic cells, are needed for chemotherapeutic agents to improve cure rates of epithelial malignancies, with acceptable toxicity. In recent years, agents inhibiting signal transduction pathway molecules have entered clinical trials. These include antibodies and small molecules, which inhibit growth factor receptors and their receptor tyrosine kinases, inhibitors of cytoplasmic second messengers such as ras, raf and MEK, inhibitors of protein trafficking, and inhibitors of protein degradation. Keywords: signal transduction pathway, cell proliferation, SCLC patient, monoclonal antibodies, anti HER 2 Antibodies, Trastuzumab, Intracellular Signaling, Vascular endothelia, Antisense Oligonucleotides, Farnesyltransferase inhibitors, MEk
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Targets of toxins that evolved to kill competing microorganisms are components of signal transduction cascades conserved in many species.
“In many cases, the targets of these compounds are components of signal transduction cascades that are conserved in many species [213].”
From Marine Natural Products: A Source of Novel Anticancer Drugs (2019) · cites this paper as [213]
Citations
Cited by
Sorted by citations
Chang, F., Steelman, L. S., Lee, J. T., Shelton, J. G., Navolanic, P. M., Blalock, W. L., Franklin, R. A., & McCubrey, J. A. (2003) · Leukemia · doi:10.1038/sj.leu.2402945 · Cited by 738
Natural products in anticancer therapy
Ab, D. R. (2001) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(01)00063-7 · Cited by 618
Marine Natural Products: A Source of Novel Anticancer Drugs
Khalifa, S. A. M., Elias, N., Farag, M. A., Chen, L., Saeed, A., Hegazy, M.-E. F., Moustafa, M. S., Abd El-Wahed, A., Al-Mousawi, S. M., Musharraf, S. G., et al. (2019) · Marine Drugs · doi:10.3390/md17090491 · Cited by 555
Cell-cell communication: New insights and clinical implications
Su, J., Song, Y., Zhu, Z., Huang, X., Fan, J., Qiao, J., & Mao, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01888-z · Cited by 433
(2011) · International Journal of Phytomedicine · Cited by 203
Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma
Zhuang, L., Lee, C. S., Scolyer, R. A., McCarthy, S., Palmer, A. A., Zhang, X. D., Thompson, J. F., Bron, L. P., & Hersey, P. (2005) · Journal of Clinical Pathology · doi:10.1136/jcp.2005.025957 · Cited by 85
Fibroblast growth factors in cancer: therapeutic possibilities
Jeffers, M., LaRochelle, W. J., & Lichenstein, H. S. (2002) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.6.4.469 · Cited by 63
Colored Petri net modeling and simulation of signal transduction pathways
Lee, D., Zimmer, R., Lee, S. Y., & PARK, S. (2005) · Metabolic Engineering · doi:10.1016/j.ymben.2005.10.001 · Cited by 50
“To date, numerous drug targets for cancer therapies have been identified at different levels in the signaling pathways (Adjei, 2000).”
BackgroundNovel Anticancer Agents in Clinical Development
Adjei, A. A., & Rowinsky, E. K. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.218 · Cited by 48
Self-citationYamagishi, K., Onuma, K., Chiba, Y., Yagi, S., Aoki, S., Sato, T., Sugawara, Y., Hosoya, N., Saeki, Y., Takahashi, M., et al. (2011) · Gut · doi:10.1136/gutjnl-2011-300721 · Cited by 49
The Akt/mTOR and Mitogen-Activated Protein Kinase Pathways in Lung Cancer Therapy
Papadimitrakopoulou, V. A., & Adjei, A. A. (2006) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)30399-3 · Cited by 40
Self-citationThe Role of Mitogen-Activated ERK-Kinase Inhibitors in Lung Cancer Therapy
Adjei, A. A. (2005) · Clinical Lung Cancer · doi:10.3816/clc.2005.n.040 · Cited by 34
Self-citationClinical Overview of Sorafenib in Breast Cancer
Moreno‐Aspitia, A. (2010) · Future Oncology · doi:10.2217/fon.10.41 · Cited by 30
Role of EGCG in Containing the Progression of Lung Tumorigenesis – A Multistage Targeting Approach
Dhatwalia, S. K., Kumar, M., & Dhawan, D. K. (2018) · Nutrition and Cancer · doi:10.1080/01635581.2018.1445762 · Cited by 26
Genetically Engineered Rodent Models of Mammary Gland Carcinogenesis: An Overview
Blackshear, P. E. (2001) · Toxicologic Pathology · doi:10.1080/019262301301418919 · Cited by 22
“Several key therapeutic targets have emerged from the study of GEM expressing c-myc, c-ras, c-neu, and matrix metalloproteinase transgenes (2, 41).”
BackgroundThe Akt/mTOR and Mitogen-Activated Protein Kinase Pathways in Lung Cancer Therapy
Papadimitrakopoulou, V. A., & Adjei, A. A. (2006) · Journal of Thoracic Oncology · doi:10.1097/01243894-200609000-00031 · Cited by 22
Self-citationBrown, A. P., Dunstan, R. W., Courtney, C. L., Criswell, K. A., & Graziano, M. J. (2008) · Toxicologic Pathology · doi:10.1177/0192623308315827 · Cited by 21
“Receptor binding results in the initiation of intracellular signal transduction pathways that ultimately influence cell growth, survival, phenotype, and proliferation (Raymond et al., 2000; Adjei, 2000).”
BackgroundIFNs-signaling effects on lung cancer: an up-to-date pathways-specific review
Galani, V., Kastamoulas, M., Varouktsi, A., et al. (2016) · Clinical and Experimental Medicine · doi:10.1007/s10238-016-0432-3 · Cited by 18
Doğan, İ., Ozkan, A. C., & Ekmekçi, A. (2015) · Tumor Biology · doi:10.1007/s13277-015-3671-0 · Cited by 17
Inhibitors of Raf kinase and MEK signaling
Ramnath, N., & Adjei, A. A. (2007) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2007.10.001 · Cited by 18
Self-citationNovel pharmacological agents in clinical development for solid tumours
Dy, G. K., Haluska, P., & Adjei, A. A. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.12.2059 · Cited by 17
Self-citationYounis, A., Riaz, A., Javaid, F., Ahsan, M. T., Tariq, U., Aslam, S., & Asif, M. (2015) · Time to knit · doi:10.51847/vulzsqgqhh · Cited by 9
Overview of Novel Anticancer Drug Targets
Buolamwini, J. K., & Assefa, H. (2003) · Humana Press eBooks · doi:10.1385/1-59259-380-1:03 · Cited by 3
Kim, L. (2008) · Cited by 2
Pandey, A., & Tripathi, S. (2014) · International Research Journal of Pharmacy · doi:10.7897/2230-8407.050206 · Cited by 1
Regulation of Cell Cycle and Apoptosis
Miele, L. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-401-6_5 · Cited by 1
Control of Proliferation in the Normal and Neoplastic Breast
Clarke, R. B., Howell, A., & Anderson, E. (2002) · Breast Cancer · doi:10.3109/9780203909249-6 · Cited by 1
Serine/Threonine Kinases and Phosphatases
Girault, J. (2002) · Wiley Encyclopedia of Molecular Medicine · doi:10.1002/0471203076.emm1020 · Cited by 1
A SURVEY OF NOVEL MOLECULAR TARGETS FOR ANTICANCER DRUG DISCOVERY
Buolamwini, J. K. (2006) · Elsevier eBooks · doi:10.1016/b978-012088561-9/50002-8
Serine/Threonine Kinases and Phosphatases
Girault, J. (2002) · Encyclopedia of Molecular Biology · doi:10.1002/047120918x.emb1408
Wortmannin as Targeted Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer
Li, J., Liu, F., Liu, Y., Du, J., & Liu, Q. (2016) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v15i1.13 · Cited by 1
“Targeting signal transduction cascades by involvement of bioactive compounds is believed to be a promising strategy for carcinoma therapy [11].”
BackgroundPirker, R. (2004) · Springer eBooks · doi:10.1007/978-3-662-06670-6_16
Control of Proliferation in the Normal and Neoplastic Breast
Clarke, R. B., Howell, A., & Anderson, E. L. (2002) · Breast Cancer · doi:10.1201/b14039-4
Marine Derived Pharmaceuticals in Biomedical Research: Current Developments and Future Prospects
Kumar, Y. S., & Swarnalatha, G. V. (2023) · Springer eBooks · doi:10.1007/978-981-99-6770-4_5 · Cited by 1
Metadata
- Authors
- Adjei, A.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Adjei, Alex
- ORCID
- Adjei, Alex
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2000-03-01
- Volume
- 6
- Issue
- 4
- Pages
- 361-378
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2093602335
- Cited by
- 33
- References
- 0
- Citations by year
- 2024: 1 · 2023: 1 · 2019: 1 · 2018: 1 · 2016: 2 · 2015: 2 · 2014: 1
- FWCI
- 1.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Pharmaceutical Design (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5k01ca077112-05)
- National Cancer Institute (CA77112)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- signaling pathways, anticancer drug discovery, epithelial cancers, monoclonal antibodies, trastuzumab, HER2, farnesyltransferase inhibitors, antisense oligonucleotides, small molecule inhibitors, cell proliferation, small cell lung cancer, vascular endothelium
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Drug Design, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
